William Haley1, Fayaz Shawl2, W Charles Sternbergh3, Tanya N Turan4, Kevin Barrett5, Jenifer Voeks4, Thomas Brott5, James F Meschia6. 1. Department of Hypertension and Nephrology (retired), Mayo Clinic, Jacksonville, FL, United States. 2. Department of Interventional Cardiology, White Oak Medical Center, Silver Springs, MD, United States. 3. Department of Vascular Surgery, Ochsner Health System, New Orleans, LA, United States. 4. Department of Neurology, Medical University of South Carolina, Charleston, SC, United States. 5. Department of Neurology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, United States. 6. Department of Neurology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, United States. Electronic address: meschia.james@mayo.edu.
Abstract
IMPORTANCE: Hypertension and carotid stenosis are both risk factors for stroke, but the presence of carotid stenosis might dampen enthusiasm for tight control of hypertension because of concerns for hypoperfusion. OBJECTIVE: To determine the extent to which there are opportunities to potentially improve pharmacotherapy for hypertension in patients known to have asymptomatic high-grade carotid stenosis. DESIGN: We examined anti-hypertensive medication prescription and adherence to evidence-based hypertension treatment guidelines in a cross-sectional analysis of baseline data of patients enrolled in a clinical trial. SETTING: The Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) is a multicenter prospective randomized open blinded end-point clinical trial of intensive medical management with or without revascularization by endarterectomy or stenting for asymptomatic high-grade carotid stenosis. PARTICIPANTS: 1479 participants (38.6% female; mean age 69.8 years) from 132 clinical centers enrolled in the CREST-2 trial as of April 6, 2020 who were taking ≥1 antihypertensive drug at baseline. EXPOSURES: Pharmacotherapy for hypertension. MAIN OUTCOME: Adherence to evidence-based guidelines for treating hypertension. RESULTS: Of 1458 participants with complete data, 26% were on one, 31% on 2, and 43% on ≥3 antihypertensive medications at trial entry. Thirty-two percent of participants were prescribed thiazide; 74%, angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB); 38%, calcium channel blocker (CCB); 56%, a beta blocker; 11%, loop diuretic; and 27%, other. Of those prescribed a single antihypertensive medication, the proportion prescribed thiazide was 5%; ACEI or ARB, 55%, and CCB, 11%. The prevalence of guideline-adherent regimens was 34% (95% CI, 31-36%). CONCLUSIONS AND RELEVANCE: In a diverse cohort with severe carotid disease and hypertension, non-adherence to hypertension guidelines was common. All preferred classes of antihypertensive drug were under-prescribed. Using staged iterative guideline-based care for hypertension, CREST-2 will characterize drug tolerance and stroke rates under these conditions. TRIAL REGISTRATION: ClinicalTrials.gov Number NCT02089217.
IMPORTANCE: Hypertension and carotid stenosis are both risk factors for stroke, but the presence of carotid stenosis might dampen enthusiasm for tight control of hypertension because of concerns for hypoperfusion. OBJECTIVE: To determine the extent to which there are opportunities to potentially improve pharmacotherapy for hypertension in patients known to have asymptomatic high-grade carotid stenosis. DESIGN: We examined anti-hypertensive medication prescription and adherence to evidence-based hypertension treatment guidelines in a cross-sectional analysis of baseline data of patients enrolled in a clinical trial. SETTING: The Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) is a multicenter prospective randomized open blinded end-point clinical trial of intensive medical management with or without revascularization by endarterectomy or stenting for asymptomatic high-grade carotid stenosis. PARTICIPANTS: 1479 participants (38.6% female; mean age 69.8 years) from 132 clinical centers enrolled in the CREST-2 trial as of April 6, 2020 who were taking ≥1 antihypertensive drug at baseline. EXPOSURES: Pharmacotherapy for hypertension. MAIN OUTCOME: Adherence to evidence-based guidelines for treating hypertension. RESULTS: Of 1458 participants with complete data, 26% were on one, 31% on 2, and 43% on ≥3 antihypertensive medications at trial entry. Thirty-two percent of participants were prescribed thiazide; 74%, angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB); 38%, calcium channel blocker (CCB); 56%, a beta blocker; 11%, loop diuretic; and 27%, other. Of those prescribed a single antihypertensive medication, the proportion prescribed thiazide was 5%; ACEI or ARB, 55%, and CCB, 11%. The prevalence of guideline-adherent regimens was 34% (95% CI, 31-36%). CONCLUSIONS AND RELEVANCE: In a diverse cohort with severe carotid disease and hypertension, non-adherence to hypertension guidelines was common. All preferred classes of antihypertensive drug were under-prescribed. Using staged iterative guideline-based care for hypertension, CREST-2 will characterize drug tolerance and stroke rates under these conditions. TRIAL REGISTRATION: ClinicalTrials.gov Number NCT02089217.
Authors: Leonie M M Fassaert; Nathalie Timmerman; Ian D van Koeverden; Gerard Pasterkamp; Dominique P V de Kleijn; Gert J de Borst Journal: Atherosclerosis Date: 2019-09-22 Impact factor: 5.162
Authors: J F Meschia; T G Brott; F E Chukwudelunzu; J Hardy; R D Brown; I Meissner; L J Hall; E J Atkinson; P C O'Brien Journal: Stroke Date: 2000-05 Impact factor: 7.914
Authors: Tara I Chang; Gregory Evans; Alfred K Cheung; William C Cushman; Matthew J Diamond; Jamie P Dwyer; Yonghong Huan; Dalane Kitzman; John B Kostis; Suzanne Oparil; Anjay Rastogi; Christianne L Roumie; Rukmani Sahay; Randall S Stafford; Addison A Taylor; Jackson T Wright; Glenn M Chertow Journal: Hypertension Date: 2016-01-25 Impact factor: 10.190
Authors: Stevo Julius; Michael A Weber; Sverre E Kjeldsen; Gordon T McInnes; Alberto Zanchetti; Hans R Brunner; John Laragh; M Anthony Schork; Tsushung A Hua; John Amerena; Ivan Balazovjech; Graham Cassel; Bela Herczeg; Nevres Koylan; Dieter Magometschnigg; Silja Majahalme; Felipe Martinez; Willie Oigman; Ricardo Seabra Gomes; Jun-ren Zhu Journal: Hypertension Date: 2006-07-24 Impact factor: 10.190
Authors: David M Reboussin; Norrina B Allen; Michael E Griswold; Eliseo Guallar; Yuling Hong; Daniel T Lackland; Edgar Pete R Miller; Tamar Polonsky; Angela M Thompson-Paul; Suma Vupputuri Journal: Circulation Date: 2018-10-23 Impact factor: 29.690
Authors: Bruce M Psaty; Thomas Lumley; Curt D Furberg; Gina Schellenbaum; Marco Pahor; Michael H Alderman; Noel S Weiss Journal: JAMA Date: 2003-05-21 Impact factor: 56.272